Five Deans Technology Showcases E-Cigarette Products at Dortmund Tobacco Exhibition

Sep.15.2022
Five Deans Technology Showcases E-Cigarette Products at Dortmund Tobacco Exhibition
Five Deans showcased their e-cigarettes at the Dortmund Tobacco Exhibition, featuring colorful designs and large capacities.

On September 15th at 10:00 am local time (4:00 pm Beijing time), the Dortmund Tobacco Expo grandly opened at the Dortmund Exhibition Center, covering an area of over 40,000 square meters. As a well-known OEM/ODM enterprise in the industry, Wulian Technology, a subsidiary of listed company Five Rings Group, proudly showcased its full range of electronic cigarette products at booth 1.A28, including CBD products and disposable e-cigarette series.


Visitors to the tobacco exhibition in Dortmund, Germany, had the opportunity to experience five top-notch electronic cigarette products.


Nextvapor Wudian Technology focuses on trendy designs and colorful packaging, emphasizing the currently popular large capacity and wide-mouthed products. Its brand DUNKE offers disposable electronic cigarettes, pod vapes, and accessories, while the BTBE brand's ONX disposable CBD electronic cigarette has also gained popularity among exhibition attendees for its sleek design.


Wodian Technology's electronic cigarette product line.


Widely popular in the global market, Wodian Technology boasts a comprehensive line of disposable electronic cigarettes, ranging from 2ml to a massive 16ml capacity, complying with European standards. The products come in different shapes and an array of colors that attract the attention of onlookers. Additionally, their pod vape products have a capacity of up to 5ml, catering to current customers' preference for high-capacity products.


Visitors at the Dortmund Tobacco Expo in Germany had the opportunity to try out the product line of electronic cigarettes from Wodian Technology.


Wudian Technology focuses on the research and development, production, sales, and service of electronic cigarettes. The factory covers an area of over 30,000 square meters with a monthly production capacity of up to 2400K. Since its establishment in 2017, the company has grown rapidly and now owns brands such as Dunke, BTBE, and NEXTVAPOR. Its CBD business has particularly shown impressive growth and has reached the TOP3 ranking in the CBD industry in 2021.


Exhibition poster of Wu Dian.


To read more about the latest news and reports on the Dortmund tobacco exhibition in Germany, please click on the link below.


1. This article is intended solely for internal discussion and communication within the industry, and does not make any brand or product promotions or recommendations. 2. Smoking is detrimental to health. Minors are prohibited from reading this article.


This article is an original work of 2FIRSTS Technology Co., Ltd. in Shenzhen, and its copyright and permission for use belong to the company. No individual or organization is allowed to copy, reprint, or infringe upon the company's copyright without authorization. If anyone violates these terms, the company reserves the right to pursue legal action.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11